You can buy or sell GNCA and other stocks, options, ETFs, and crypto commission-free!
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Read More Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 13
Will Genocea Biosciences Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. GNCA. The stock has moved higher by 47% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider GNCA’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as G...
Yahoo FinanceMar 7
Top Ranked Momentum Stocks to Buy for March 7th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th: La-Z-Boy Incorporated (LZB): This furniture products and accessories manufacturer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.3% over the last 60 days. La-Z-Boy Incorporated Price and Consensus Scroll to continue with content Ad La-Z-Boy Incorporated Price and Consensus La-Z-Boy Incorporated price-consensus-chart | La-Z-Bo...
Markets InsiderMar 6
Genocea to Present at the Cowen & Company 39th Annual Health Care Conference
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Cowen & Company 39th Annual Health Care Conference on Wednesday, March 13th at 11:20 A.M. ET in Boston, Massachusetts. A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the i...
Expected May 9, Pre-Market